Abstract:
:The cardinal haemodynamic disturbance in established hypertension is an increased total peripheral resistance and a subnormal blood flow, particularly during exercise. The spontaneously occurring changes in central haemodynamics have been followed in young males with essential hypertension over a 17-year period: a gradual increase in total peripheral resistance and blood pressure, and a gradual fall in cardiac output and stroke volume, have been demonstrated. Labetalol is a unique antihypertensive agent which induces both alpha- and beta-blockade. Numerous studies have shown that when labetalol is given intravenously to patients with mild to moderate essential hypertension, blood pressure falls within a few minutes-partly due to reduction in cardiac output and heart rate and partly due to reduction in total peripheral resistance. In most series the average reduction in blood pressure was 17 to 22%, the reduction in total peripheral resistance 11 to 14%, and the reduction in cardiac output 2 to 10%. Thus, the reduction in cardiac output with labetalol is less than that seen after single-dose injection of beta-blockers without intrinsic sympathomimetic activity. After intravenous injection, the blood pressure-lowering effect is most marked in the upright position and during muscular exercise when cardiac output is usually significantly reduced. Labetalol reduces blood pressure in severe hypertension. Intravenous doses of 0.2 to 0.8 mg/kg bodyweight reduce blood pressure by approximately 20%. This hypotensive effect is partly due to a reduction in total peripheral resistance and partly due to a fall in cardiac index. When the reduction in blood pressure is gradual and moderate (less than 20%), it is mainly produced by a reduction in total peripheral resistance. During long term use labetalol induces haemodynamic changes rather similar to those seen after bolus injection. However, during prolonged use there is a tendency to normalisation in cardiac output and stroke volume; the sustained decrease in blood pressure is mainly due to a reduction in total peripheral resistance. In a recent 6-year follow-up study where 15 patients were studied before treatment and after 1 and 6 years on long term labetalol treatment, a tendency to normalisation of central haemodynamics was found. Over the years total peripheral resistance was gradually reduced by 15 to 20% at rest as well as during exercise. Stroke volume gradually increased and after 6 years of treatment was approximately 10% higher than the pretreatment value. This compensated for the reduced heart rate and no significant reduction in cardiac output was seen either during exercise or at rest.(ABSTRACT TRUNCATED AT 400 WORDS)
journal_name
Drugsjournal_title
Drugsauthors
Lund-Johansen Pdoi
10.2165/00003495-198400282-00004subject
Has Abstractpub_date
1984-01-01 00:00:00pages
35-50eissn
0012-6667issn
1179-1950journal_volume
28 Suppl 2pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::An acute thrombus at the site of an atherosclerotic obstruction is the usual cause of myocardial infarction. Thrombolytic therapy is an exciting new therapy for reducing the extent of myocardial infarction by lysing intracoronary clots. Such therapy has now been widely applied by: prolonged intravenous infusion of str...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198428050-00004
更新日期:1984-11-01 00:00:00
abstract::During depression, chronobiological disorders occur, such as disturbances in body temperature and early urinary excretion of a noradrenaline metabolite. Sleep patterns are disturbed in 90% of depressed patients; early REM sleep and shortened slow-wave sleep (stages 3 and 4), resulting in an increase in REM sleep, have...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198900381-00003
更新日期:1989-01-01 00:00:00
abstract::With changing donor characteristics and the growing shortage in organ supply, renal transplant practitioners have sought to optimize the use of expanded criteria donor (ECD) kidneys, which have poorer outcomes than standard criteria donor (SCD) kidneys. The outcomes may represent an acceptable trade-off if ECD transpl...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868001-00006
更新日期:2008-01-01 00:00:00
abstract::The pharmacokinetics of different formulations of glyceryl trinitrate, isosorbide dinitrate, isosorbide 5-mononitrate and isosorbide 2-mononitrate are reviewed. ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198700334-00004
更新日期:1987-01-01 00:00:00
abstract::Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity excee...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0541-z
更新日期:2016-03-01 00:00:00
abstract::Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the body surface area (BSA). Although many physiological functions are proportionate to BSA, overall drug clearance is only partially related to this parameter. Consequently, following administration of equivalent drug dosages based...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856060-00006
更新日期:1998-12-01 00:00:00
abstract::Treatment of idiopathic membranous nephropathy is based on a 'symptomatic' therapy that includes ACE inhibitors or angiotensin II receptor antagonists, and on an 'aetiological' therapy aimed at modulating underlying immunological mechanisms. The role of the latter is still debated given the usually indolent course of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200969100-00002
更新日期:2009-07-09 00:00:00
abstract::Chronic pancreatitis is a clinical entity that results from the progressive inflammation and irreversible fibrosis of the pancreas resulting from the cumulative injury sustained by the pancreas over time. It is an illness with variable presentations that can severely impact quality of life, while its long-term complic...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-020-01360-6
更新日期:2020-08-01 00:00:00
abstract::Suvorexant (Belsomra(®)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neuro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0294-5
更新日期:2014-10-01 00:00:00
abstract::Liposomes are versatile drug carriers which can be used to solve problems of drug solubility, instability and rapid degradation. Both hydrophilic and hydrophobic drugs can be associated with liposomes and special techniques have been developed for the efficient loading of weak acids and weak bases into liposomes. Lipo...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856050-00001
更新日期:1998-11-01 00:00:00
abstract::Valsartan/hydrochlorothiazide is a fixed-dose (valsartan 80, 160 or 320mg plus hydrochlorothiazide 12.5 or 25mg) angiotensin II receptor blocker/diuretic drug combination indicated for the treatment of patients with essential hypertension not adequately controlled by monotherapy.There is ample evidence that valsartan/...
journal_title:Drugs
pub_type: 杂志文章,meta分析,评审
doi:10.2165/00003495-200666140-00011
更新日期:2006-01-01 00:00:00
abstract::Arachidonic acid is normally stored in membrane-bound phospholipids and released by the action of phospholipases. Enzymatic conversion of released arachidonic acid into biologically active derivatives proceeds through one of several routes. Cyclo-oxygenase converts arachidonic acid to unstable cyclic endoperoxides fro...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198700331-00003
更新日期:1987-01-01 00:00:00
abstract::This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a trans...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0377-y
更新日期:2015-04-01 00:00:00
abstract:UNLABELLED:Zolpidem is an imidazopyridine agent that is indicated for the short term (< or = 4 weeks) treatment of insomnia (recommended dosage 10 mg/day in adults and 5 or 10 mg/day in the elderly or patients with hepatic impairment). Data have shown that the hypnotic efficacy of zolpidem is generally comparable to th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200059040-00014
更新日期:2000-04-01 00:00:00
abstract:UNLABELLED:Oral delayed-release mesalazine is an enteric-coated formulation which releases mesalazine in the terminal ileum and colon. Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-rel...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199957030-00013
更新日期:1999-03-01 00:00:00
abstract::Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity. The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198836030-00002
更新日期:1988-09-01 00:00:00
abstract::Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01250-6
更新日期:2020-01-01 00:00:00
abstract::Despite well known complications, oral nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most commonly prescribed medications in the US for musculoskeletal disorders such as osteoarthritis. Although there has been a recent focus on the cardiovascular and renal complications associated with these agents, NSAID g...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11633740-000000000-00000
更新日期:2012-05-07 00:00:00
abstract::Methylnaltrexone is a selective mu-opioid receptor antagonist that has restricted ability to cross the blood-brain barrier, thus enabling reversal of opioid-induced peripheral effects, such as constipation, without affecting the central effects, such as pain relief. Treatment with subcutaneous methylnaltrexone 0.15-0....
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11204520-000000000-00000
更新日期:2010-05-07 00:00:00
abstract::Part I of this article reviewed the targets against which anti-HIV drugs can be directed, problems in assessing active compounds (e.g. resistance development and use of surrogate end-points). and nucleoside analogues effective against HIV reverse transcriptase. Intensive research is currently being undertaken in labor...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199345050-00002
更新日期:1993-05-01 00:00:00
abstract::Multiple sclerosis (MS) is thought to be a chronic inflammatory disorder of the CNS. The past decade has seen the introduction of the new immunomodulatory drugs, interferon (IFN)-beta and glatiramer acetate, that have considerably improved the therapeutic options for this often disabling disease. The efficacy of these...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363150-00001
更新日期:2003-01-01 00:00:00
abstract::Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01230-w
更新日期:2019-12-01 00:00:00
abstract::When used to treat patients with Parkinson's disease pergolide acts at dopamine receptors in the corpus striatum to improve locomotor activity, reducing the tremor, gait disturbances, bradykinesia or akinesia and rigidity experienced by such patients. Treatment with pergolide often allows substantial reductions in con...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199039030-00009
更新日期:1990-03-01 00:00:00
abstract::Everolimus is an immunosuppressant that blocks growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Oral everolimus 0.75 or 1.5mg twice daily significantly reduced the incidence of the primary composite endpoint, efficacy failure 6 months after transplantation, compared with azathioprine...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200464080-00005
更新日期:2004-01-01 00:00:00
abstract::Eltrombopag (Revolade(®)) is an orally bioavailable, low molecular weight, synthetic nonpeptide thrombopoietin receptor agonist, which selectively binds to the transmembrane and juxtamembrane domains of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte precursor cells, resulting...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11207390-000000000-00000
更新日期:2011-07-09 00:00:00
abstract::An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198224030-00003
更新日期:1982-09-01 00:00:00
abstract::HIV causes chronic infection and is associated with persistent viral replication and a high viral mutation rate. It is an illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease. Monotherapy with antitubercular agents led to dramatic improvements in treatme...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199500491-00008
更新日期:1995-01-01 00:00:00
abstract::Crizotinib (Xalkori(®)) is an orally active, small molecule inhibitor of multiple receptor tyrosine kinases, including anaplastic lymphoma kinase (ALK), c-Met/hepatocyte growth factor receptor and c-ros oncogene 1. In the EU, crizotinib has been conditionally approved for the treatment of adults with previously treate...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0142-z
更新日期:2013-12-01 00:00:00
abstract::Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1....
journal_title:Drugs
pub_type: 杂志文章,评审
doi:
更新日期:2003-01-01 00:00:00
abstract::Clostridium difficile-associated disease (CDAD) is increasingly being reported in many regions throughout the world. The reasons for this are unknown, are likely to be multifactorial, and are the subject of several current investigations. In addition to the upsurge in frequency of CDAD, an increased rate of relapse/re...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767040-00001
更新日期:2007-01-01 00:00:00